Aug. 4 at 9:31 PM
$LNAI
Lunai (LNAI) Through its subsidiary BioSymetrics, took an existing public dataset of Parkinson’s patients (the PPMI study) and ran pattern-finding software over it. The output: Parkinson’s isn’t one disease, actually it splits into groups that progress differently. Fast motor decline, cognitive decline, and a female-enriched group. Lunai produces the analysis.
BrainStorm Therapeutics is the biology side. It grows small clumps of human brain tissue (“midbrain organoids”) from actual Parkinson’s patients, specifically from people with inherited forms of the disease, where the genetic cause is known. That gives them living human tissue to experiment on.
Why they need each other: a computer saying “these patients look like a distinct group” is a hypothesis. Until someone tests it in human tissue, it stays a hypothesis. BrainStorm is the test rig.
Ohh, by the way there is one caution worth verifying: BrainStorm Therapeutics (San Diego, private, CEO Robert Fremeau) is a different company from BrainStorm Cell Therapeutics, which trades on Nasdaq. Similar names, unrelated. Easy mistake for an investor to make in the wrong direction. https://ir.lunaibioworks.com/news/news-details/2026/Lunai-Bioworks-Nasdaq-LNAI-Signs-Definitive-Collaboration-Agreement-with-BrainStorm-Therapeutics-Initial-Parkinsons-Disease-Data-Readout-Targeted-for-First-Half-of-2027/default.aspx
